You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

OX40

Showing 1 - 25 of 600
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Solid Tumor, Adult Lymphoma Trial (HLX51)

Not yet recruiting
  • Solid Tumor, Adult Lymphoma
  • (no location specified)
Mar 15, 2023

Colorectal Tumors Trial in Portland (MEDI6469)

Terminated
  • Colorectal Neoplasms
  • Portland, Oregon
    Portland Providence Medical Center
Jan 31, 2022

Advanced Malignant Solid Tumor, Extracranial Solid Tumor, Metastatic Malignant Solid Tumor Trial in Palo Alto (Anti-OX40

Active, not recruiting
  • Advanced Malignant Solid Neoplasm
  • +2 more
  • Anti-OX40 Antibody BMS 986178
  • TLR9 Agonist SD-101
  • Palo Alto, California
    Stanford Cancer Institute Palo Alto
Jun 13, 2022

Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Cancer, Recurrent Renal Cell Carcinoma Trial in United States

Active, not recruiting
  • Clear Cell Renal Cell Carcinoma
  • +3 more
  • Anti-OX40 Antibody PF-04518600
  • +3 more
  • Los Angeles, California
  • +9 more
Aug 5, 2022

Solid Tumors, Tumors, Malignant Tumor Trial in Changchun (ES102)

Active, not recruiting
  • Solid Tumors
  • +2 more
  • Changchun, Jilin, China
    Jilin Cancer Hospital
Oct 19, 2022

Locally Advanced Malignant Solid Tumor, Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 Trial in United

Recruiting
  • Locally Advanced Malignant Solid Neoplasm
  • +3 more
  • Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949
  • VLP-encapsulated TLR9 Agonist CMP-001
  • Scottsdale, Arizona
  • +3 more
Jun 1, 2022

Hidradenitis Suppurativa Trial (SAR442970, Placebo)

Not yet recruiting
  • Hidradenitis Suppurativa
  • (no location specified)
Apr 28, 2023

B-Cell Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma Trial in Palo Alto (biological, other,

Active, not recruiting
  • B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Anti-OX40 Antibody BMS 986178
  • +3 more
  • Palo Alto, California
    Stanford University, School of Medicine
May 3, 2022

Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Houston (Anti-OX40 Agonist Monoclonal Antibody

Active, not recruiting
  • Recurrent Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Anti-OX40 Agonist Monoclonal Antibody PF-04518600
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 25, 2022

Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma Trial (BGB-A445, Tislelizumab)

Not yet recruiting
  • Urothelial Carcinoma
  • +2 more
  • (no location specified)
Dec 15, 2022

Advanced Solid Tumor Trial (EMB-09)

Not yet recruiting
  • Advanced Solid Tumor
  • EMB-09
  • (no location specified)
Feb 22, 2022

Solid Tumor, Tumors, Malignant Tumor Trial in Changchun (ES102, JS001)

Recruiting
  • Solid Tumor
  • +2 more
  • Changchun, Jilin, China
    Jilin Cancer Hospital
Oct 28, 2021

Advanced Solid Tumour Trial (BAT6026, BAT1308)

Not yet recruiting
  • Advanced Solid Tumour
  • (no location specified)
Oct 27, 2021

Squamous Cell Carcinoma of the Head and Neck, Melanoma, Non Small Cell Lung Cancer Trial in Worldwide (SL-279252)

Recruiting
  • Squamous Cell Carcinoma of the Head and Neck
  • +12 more
  • Nashville, Tennessee
  • +4 more
Feb 3, 2022

Advanced Solid Tumors Trial in Guangzhou (BAT6026)

Recruiting
  • Advanced Solid Tumors
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Dec 23, 2021

Carpal Tunnel Syndrome, Neurodynamic Treatment, Nerve Mobilisation Trial in Oxford (Neurodynamic exercises, Steroid injection

Recruiting
  • Carpal Tunnel Syndrome
  • +5 more
  • Neurodynamic exercises
  • +2 more
  • Oxford, Oxfordshire, United Kingdom
    Nuffield Department of Clinical Neurosciences, University of Oxf
May 4, 2023

Liver Metastases, Liver Metastasis Colon Cancer, Colorectal Cancer Trial in Tampa (DNX-2440)

Recruiting
  • Liver Metastases
  • +10 more
  • DNX-2440
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute, Inc.
Mar 28, 2022

Advanced Cancer, Metastatic Cancer Trial in Spain, United States (FS120)

Recruiting
  • Advanced Cancer
  • Metastatic Cancer
  • New Haven, Connecticut
  • +7 more
Aug 8, 2022

Soft Tissue Sarcoma, Renal Cell Carcinoma, Uterine Carcinosarcoma Trial in United States (HFB301001)

Recruiting
  • Soft Tissue Sarcoma
  • +4 more
  • Scottsdale, Arizona
  • +9 more
Sep 13, 2022

Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Ovarian Cancer Trial in United States (mRNA-2416, Durvalumab)

Terminated
  • Relapsed/Refractory Solid Tumor Malignancies or Lymphoma
  • Ovarian Cancer
  • mRNA-2416
  • Durvalumab
  • Aurora, Colorado
  • +8 more
Jul 7, 2022

Advanced Solid Tumor Trial in Australia, New Zealand, United States (BGB-A445, tislelizumab)

Recruiting
  • Phase 1a:Advanced Solid Tumors; Phase 1b: Non-small Cell Lung Cancer (NSCLC) and Head and Neck Squamous Cell Carcinoma (HNSCC)
  • Pittsburgh, Pennsylvania
  • +11 more
Aug 25, 2022

Epithelial Tumor, Metastatic Cancer Trial in United Kingdom, United States (NG-350A plus Pembrolizumab)

Recruiting
  • Epithelial Tumor
  • Metastatic Cancer
  • NG-350A plus Pembrolizumab
  • Santa Monica, California
  • +3 more
May 4, 2022

Dermatitis, Atopic Trial in Worldwide (KY1005, Placebo)

Completed
  • Dermatitis, Atopic
  • Kiel, Germany
  • +18 more
Apr 30, 2021

Eczema, Atopic Dermatitis Trial in Worldwide (KY1005, Placebo)

Active, not recruiting
  • Eczema
  • Atopic Dermatitis
  • Fremont, California
  • +102 more
Dec 13, 2022

Tumors Trial in Worldwide (Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody, MOXR0916, a

Completed
  • Neoplasms
  • Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody
  • MOXR0916, a humanized agonist anti-OX40 monoclonal antibody
  • Scottsdale, Arizona
  • +26 more
Mar 31, 2022